Publications by authors named "K K O'Byrne"
Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions. Here, we combine time course RNA sequencing (RNA-seq) of peripheral blood mononuclear cells with pre-treatment tumor transcriptome data from the single-arm, phase 2 DREAM trial (N = 54).
View Article and Find Full Text PDFHypothalamic kisspeptin (Kiss1) neurons are vital for pubertal development and reproduction. Arcuate nucleus Kiss1 (Kiss1) neurons are responsible for the pulsatile release of gonadotropin-releasing hormone (GnRH). In females, the behavior of Kiss1 neurons, expressing Kiss1, neurokinin B (NKB), and dynorphin (Dyn), varies throughout the ovarian cycle.
View Article and Find Full Text PDFArticle Synopsis
- * A pooled analysis of clinical trials showed that patients receiving this combination treatment had better overall survival (17.4 months) compared to those receiving chemotherapy alone (11.3 months) at a median follow-up of 73.7 months.
- * The combination treatment also resulted in higher progression-free survival and objective response rates without new safety concerns, making it a promising first-line option for hard-to-treat NSCLC cases.
Article Synopsis
- ALK-positive lung cancers exhibit molecular diversity and pose challenges due to treatment resistance, prompting the need for innovative strategies using ctDNA monitoring.
- The ALKTERNATE pilot study analyzed alternating treatments of lorlatinib and crizotinib in patients resistant to previous ALK inhibitors, focusing on outcomes like treatment failure time, safety, and patient experiences.
- Results showed that the alternating therapy was safe and effective for most participants, with an average treatment failure time of 10 months and overall survival of 23 months, indicating the importance of genetic factors in treatment response.
This single-arm phase II non-randomised trial (ACTRN12619001265167) evaluated trastuzumab emtansine in solid cancers with HER2 amplification or mutation detected by comprehensive genomic profiling. The primary objective was objective response (OR), while secondary objectives included the time to progression (TTP) on study to TTP on prior therapy ratio, progression-free survival (PFS) and overall survival (OS). The cohort included 16 tumours with HER2 mutations (group 1) and 16 with HER2 amplification (group 2).
View Article and Find Full Text PDF